SUBSCRIBE: Print / eNewsletter
HIV-Positive Women Face Increased Risk of Precancerous Cervical Lesions
Women infected with the human immunodeficiency virus (HIV) are more likely to have human papillomavirus (HPV) infection that progresses to pre-cancerous cervical lesions.
Oncologists Reluctant to Give Exercise Recommendations to Cancer Patients
Both oncologists and cancer patients recognize the benefits of physical activity during treatment, but oncologists may feel ill-equipped to give recommendations on exercise, according to a new study.
MEK Inhibitor Adds No Value in Treatment of KRAS-Mutant NSCLC
Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non–small-cell lung cancer.
PET Imaging May Predict Early Immunotherapy Response
A noninvasive PET imaging method may serve as a useful predictive biomarker for responses to cancer immunotherapy, according to a new study.
Vaccine/Chemotherapy Combination Improves Survival in Glioblastoma
Cytomegalovirus targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free and overall survival in patients with newly diagnosed glioblastoma.
CheckMate 067 Shows OS Improved With Nivolumab/Ipilimumab in Melanoma
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients.
Young Obese Men at Risk for Liver Cancer
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
Novel Calculator Guides Treatment Choice in Esophageal Cancer
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.
Eating Soy Foods May Prolong Survival in Breast Cancer Patients
Some women with breast cancer may survive longer if they consume soy-based foods, according to a new study.
New Therapies for T-Cell Lymphomas on the Horizon
There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.